Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study introduces three spectrophotometric techniques for accurately determining finasteride and tadalafil in their combined pharmaceutical form, demonstrating their sustainability, sensitivity, and suitability for quality assurance, alongside a dissolution study following FDA guidelines.

This article discusses the creation of Alopecia Areata Uniform Protocols by the National Alopecia Areata Foundation to standardize clinical trials for alopecia areata treatments and reports no new results.

This study introduced and validated new spectrophotometric methods to simultaneously determine finasteride and tadalafil in Entadfi™ capsules with high sensitivity and without interference from excipients.

This report discusses the FDA's third denial of approval for Aveed, a long-acting testosterone injection by Endo Pharmaceuticals, citing continued safety concerns including severe side effects.

This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.

This manuscript reviews the multifaceted causes of female hair loss, including hormonal imbalances and nutrient deficiencies, and suggests that non-pharmaceutical options like saw palmetto and curcumin show promise in enhancing hair density, though further studies are needed to confirm their effectiveness and safety.

This article examines advancements in understanding and managing androgenic alopecia (male pattern baldness), discussing genetic and psychological factors, diagnostic methods, classifications, and various treatment options, including traditional and emerging therapies, to aid healthcare professionals in making informed treatment decisions.

This article reviews various hair growth and hair loss treatments, noting limited new developments since FDA-approved drugs but highlights recent cosmetic surgery and potential cell-based therapies; it reports no original findings.

This study identified five FDA-approved drugs—cepharantine, clofazimine, metergoline, imatinib, and efloxate—as potential candidates for repurposing to interfere with viral entry in COVID-19 treatment.

This article reviews 27 small-molecule drugs approved by the FDA in 2024, noting that among them, eight "first-in-class" drugs with breakthrough therapy status show distinct mechanisms and substantial efficacy improvements in various conditions like cancer and chronic diseases.

This review discusses both conventional and new pharmaceutical treatments for hair loss, as well as various natural and herbal remedies, but reports no new clinical results.

This article reviews drug repurposing as a strategy to overcome challenges in drug discovery, emphasizing AI and machine learning's role, but presents no new clinical results.

This review discusses the mechanisms associated with protoporphyrin IX in living cells and reports no clinical results; the authors emphasize its potential in cancer diagnosis and the risks of toxicity.

This review discusses the pathophysiology of androgen-stimulated skin disorders and key clinical trials of 5α-reductase inhibitors for their treatment, but it does not report new clinical results.

This review discusses conventional and alternative hair loss treatments, such as Minoxidil and herbal remedies, noting their effectiveness and concerns over side effects but reports no new clinical results.

In this study, researchers explored drug repurposing as a potential strategy for treating psoriasis and identified Pioglitazone, Trimipramine, and Dimetindene as promising candidates for this indication, based on molecular docking and predictive algorithms.

This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.

This article discusses the FDA approval of bremelanotide for premenopausal women with hypoactive sexual desire disorder and reports no clinical results.

Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.

This study found that two eco-friendly analytical methods for quantifying Finasteride and Tadalafil in a new dosage form were effective, green, and suitable for quality control.

This narrative review discusses the advantages of bidirectional barbed sutures in wound closure, such as faster placement and no need for knots, but reports no new clinical results.

This article discusses modern hair restoration surgery techniques, the concept of follicular units, and preoperative evaluation considerations, but it reports no new clinical results.

This review highlights the clinical usefulness of bimatoprost in lowering intraocular pressure for glaucoma patients and its promising results in promoting hair growth for conditions like alopecia, with research also exploring potential new applications and delivery systems.

This review classifies engineered nanomaterials by composition and application in biomedicine, highlighting diverse uses like regenerative medicine and potential occupational side effects, but reports no new clinical results.

This review explores stem cell applications for hair regrowth in alopecia, with no new clinical results, suggesting potential advantages over current FDA-approved treatments.

This study found that Facebook hair loss treatment content is primarily advertisement-driven and seldom supported by medical evidence, with user engagement being generally low for evidence-based posts.

This study prepared and evaluated a polyherbal hair oil using plant-based ingredients, finding that it met standard parameters and effectively addressed hair problems such as growth and dandruff, with FDA approval for clinical use.

This analytical review of alopecia treatments in the US found that drugs like minoxidil and finasteride are most affordable and effective, while newer JAK inhibitors show significant clinical results but are cost-prohibitive; the study stresses individualizing treatment based on financial capability and alopecia type.

In this review, the authors explored current and novel treatment options for androgenetic alopecia, noting both FDA-approved pharmacologic treatments like Minoxidil and Finasteride and various non-pharmacologic and surgical methods, including hair transplantation and scalp micro-pigmentation.

In this review, researchers discuss 50 novel drugs approved by the FDA in 2024, highlighting key agents like vadadustat for anemia in chronic kidney disease and donanemab for Alzheimer’s, and focusing on their roles in pharmacy education and clinical decision-making.